Hemophilia B, Severe - Healing Genes

Hemophilia B, Severe

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B

Phase 1


Doctors at research locations in DC, IN, and TX seek male patients with Hemophilia B currently under factor IX prophylaxis treatment to trial a new therapy called SB-FIX.  SB-FIX is a genome editing-drug that inserts a correct copy of the Factor 9 gene into the liver with the goal of lifelong therapeutic production of the Factor IX clotting factor.

Study participants will receive a single infusion of the investigatory gene therapy drug. Follow up will be assessing for adverse reactions and for FIX activity levels in the blood and will last for ~3 years.


  • Be male and 18 years or older
  • Have severe hemophilia B (native circulating FIX activity <1%, with or without cross reactive material)
  • Not have received previous gene therapy treatment
  • Be HIV-negative


  1. Screening before the treatment
  2. A single infusion of SB-FIX will be administered
  3. Monitoring of the patient for a few hours after dosing, then minimal follow up for the next 3 years.

The three study site locations are in DC, Indiana, and Texas:
Georgetown University Medical Center in Washington, DC, Map.
Indiana Hemophilia and Thrombosis Center in Indianapolis, IN, Map.
University of Texas Southwestern Medical Center in Dallas, TX, Map.
Medical Monitor  |  [email protected]
Sangamo Therapeutics
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader